NeuVasQ Biotechnologies bags €20m in Series A financing

/in /by

NeuVasQ Biotechnologies has raised €20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.

Read more

BioverSys AG bags $15m CARB-X funding

/in /by

CARB-X is funding Swiss pharma company BioVersys with $15.2m to develop a new class of antibiotics to treat infections caused by multidrug-resistant pathogens.

Read more

EU approves Biontech/Pfizer vaccine for adolescents

/in /by

The European Medicines Agency (EMA) has given the green light for vaccination of adolescents with Biontech’s COVID-19 vaccine Comirnaty (BNT162b2).

Read more

Senti Bio and Bluerock ink Regmed collaboration

/in /by

Senti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms.

Read more

Pieris in $1.4bn deal with Roche

/in /by

German-US Anticalin specialist Pieris Pharmaceuticals has bagged $20m upfront for a strategic R&D and license agreement with Genentech, the US branch of Swiss Roche AG.

 

 

Read more

Associations call for acceleration of ATMP trials in Europe

/in /by

Life science associations are calling for ATMPs to be exempted from the strict EU GMO rules, as their different legal interpretations in EU member states are delaying applications for multicentre clinical trials.

Read more

COVID-19 med APN01 selected to be tested in ACTIV study

/in /by

APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.

Read more